This site is intended for healthcare professionals
News

First patient dosed in Greater China in global registrational clinical trial of efgartigimod in primary immune thrombocytopenia.

Read time: 1 mins
Published:12th Nov 2021
Zai Lab Limited announced that the first patient with primary immune thrombocytopenia (ITP) was treated with efgartigimod in Greater China (mainland China, Hong Kong, Macau, and Taiwan) as part of the global registrational ADVANCE-SC Phase III study.

The ADVANCE-SC study is a randomized, double-blind, placebo-controlled, multi-center Phase III trial evaluating the efficacy and safety of subcutaneous (SC) efgartigimod in approximately 156 adult patients with primary ITP.

In a prior Phase II study, patients treated with efgartigimod exhibited clinically meaningful improvement in platelet counts across doses and types of ITP patients (newly diagnosed, persistent and chronic), and this benefit strongly correlated with reduction in IgG levels. This data highlights the potency of efgartigimod in this difficult-to-treat disease. Efgartigimod has the potential to treat ITP in a novel way, targeting the disease at its source by eliminating autoantibodies and restoring platelet counts. Also, efgartigimod appears to be well tolerated, potentially because of its unique structure and ability to bind to the FcRn receptor.

ITP is a rare and often chronic bleeding disorder in which reduced numbers of platelets can lead to an increased risk of bleeding and bruising, which impairs quality of life. In ITP, the immune system produces IgG autoantibodies that destroy platelets and affect platelet production. While ITP can be asymptomatic, minor bleeding episodes are not uncommon. Some ITP patients experience more severe bleeding episodes, including intracerebral hemorrhage.

Condition: Immune Thrombocytopenic Purpura
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.